Our principal Yolanda Wang joined the Inspo Talk “The Intersection of IP and ESG” with Annie Tsoi, Secretary General of AIPPI, as speakers at the BIP Asia Forum 2021. Topics discussed included how does IP and ESG related, suggestions on how to approach IP and ESG, ESG performance, and how should SME and startups react to ESG and preferably using IP.

Our Past Events

Eagle IP Recognized as Top Tier Firm (Tier 1) for Patent Prosecution in IP Stars 2026 Patent Firms Ranking List

5 June 2026

Eagle IP Achieves Top Ranking in 2026 IAM Patent 1000

2 June 2026

Eagle IP to Participate in AIPLA 2026 Spring Meeting in San Francisco

8 May 2026

Eagle IP has been named as the Winner of the LSPN Cross-Border Collaboration Partner of the Year Award at the LSPN Awards USA 2026

8 May 2026

Eagle IP to Attend INTA 2026 Annual Meeting in London

2 May 2026

Eagle IP’s Jennifer Che to Attend LSPN North America Spring 2026 in Boston

29 April 2026

Recommended Insights

Beijing Supreme People’s Court Upholds Novo Nordisk Semaglutide Patent in China based on Post-Filing Data

23 January 2026
On December 31, 2025, The Supreme People's Court upheld the Beijing IP Court's decision, meaning that the semaglutide patent remains valid and will expire on March 20, 2026. Novo Nordisk announced this positive news via a press release on the day the case was decided. The Chinese Ministry of Commerce has also confirmed this decision […]
Read more >

China Hands Down First Batch of Patent Linkage “Paragraph IV” Litigation Results

30 June 2022
China has been implementing a plethora of new laws and measures that are particularly favorable to drug companies, such as patent term extension and patent linkage. Details of the new implementation measures for patent linkage (technically “early dispute resolution mechanisms for drug patents”) came into effect on July 4, 2021. At around the same time, […]
Read more >

China Releases Draft Implementation Guidelines for the Drug Administration Law

2 June 2022
The latest draft implementation guidelines for China’s Drug Administration Law (“Guidelines”) are out and open for comment. Previously, the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage Measures”) came into effect on July 4, 2021. The Guidelines indicate that the final approval of generic chemical drug applications for marketing approval […]
Read more >

New Policies to Promote Importation of Innovative Drugs

8 November 2018
At the April 12, 2018 executive meeting of the State Council in China, Premier Mr. Li Keqiang indicated the government’s desire to increase China’s access to innovative drugs. To achieve this, the government would encourage importation of innovative drugs into China by streamlining the regulatory pathway, enhancing IP protection, and lowering the cost of medicine. […]
Read more >
Top crossarrow-right